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Abstract
Objective To assess the risk of venous thrombosis in current users of
non-oral hormonal contraception.
Design Historical national registry based cohort study.
Setting Four national registries in Denmark.
Participants All Danish non-pregnant women aged 15-49 (n=1 626
158), free of previous thrombotic disease or cancer, were followed from
2001 to 2010.
Main outcome measures Incidence rate of venous thrombosis in users
of transdermal, vaginal, intrauterine, or subcutaneous hormonal
contraception, relative risk of venous thrombosis compared with
non-users, and rate ratios of venous thrombosis in current users of
non-oral products compared with the standard reference oral
contraceptive with levonorgestrel and 30-40 µg oestrogen. Diagnoses
were confirmed by at least four weeks of anticoagulation therapy after
the diagnosis.
Results Within 9 429 128 woman years of observation, 5287 first ever
venous thrombosis events were recorded, of which 3434 were confirmed.
In non-users of hormonal contraception the incidence rate of confirmed
events was 2.1 per 10 000 woman years. Compared with non-users of
hormonal contraception, and after adjustment for age, calendar year,
and education, the relative risk of confirmed venous thrombosis in users
of transdermal combined contraceptive patches was 7.9 (95% confidence
interval 3.5 to 17.7) and of the vaginal ring was 6.5 (4.7 to 8.9). The
corresponding incidences per 10 000 exposure years were 9.7 and 7.8
events. The relative risk was increased in women who used
subcutaneous implants (1.4, 0.6 to 3.4) but not in those who used the
levonorgestrel intrauterine system (0.6, 0.4 to 0.8). Compared with users
of combined oral contraceptives containing levonorgestrel, the adjusted
relative risk of venous thrombosis in users of transdermal patches was
2.3 (1.0 to 5.2) and of the vaginal ring was 1.9 (1.3 to 2.7).
Conclusion Women who use transdermal patches or vaginal rings for
contraception have a 7.9 and 6.5 times increased risk of confirmed
venous thrombosis compared with non-users of hormonal contraception
of the same age, corresponding to 9.7 and 7.8 events per 10 000
exposure years. The risk was slightly increased in women using
subcutaneous implants but not in those using the levonorgestrel
intrauterine system.
Introduction
Several studies have assessed the risk of venous thrombosis in
womenusingoralcontraceptives.
1-10However,nonehasassessed
the risk in women using subcutaneous hormonal implants. A
recent study reported a 48% higher risk of venous thrombosis
in women using a vaginal ring compared with those using
combined oral contraceptives containing levonorgestrel,
11 and
a few studies have reported the risk in women using a
transdermalcombinedcontraceptivepatch,althoughtheresults
were conflicting.
12-16
Using a historical national registry based cohort study design,
weassessedtheabsoluteandrelativeriskofvenousthrombosis
in Danish women using non-oral hormonal contraception.
Methods
Information on the four national data sources that provided
information for the study is provided in detail elsewhere.
10
Briefly, from Statistics Denmark we obtained data on length of
schooling, ongoing or finished education, vital status, and
emigration of all Danish women aged 15-49 from 1 January
2001 to 31 December 2010. We censored women in cases of
death or emigration.
Since 1977 the national registry of patients has collected
discharge diagnoses from all public and private hospitals in
Denmark (see appendix for a list of the relevant diagnoses and
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Research
RESEARCHcodes used in this study). To include only first ever events, we
excludedwomenwithanytypeofvenousorarterialthrombotic
event before the study period (1977-2000), those with cancer,
those who had undergone bilateral oophorectomy or
hysterectomy, and those who had been sterilised. From study
follow-up we censored a woman’s risk time during pregnancy,
calculated from conception to three months after delivery, and
women with a coagulation disorder from the first time such a
diagnosis was recorded (appendix). The registry records only
women admitted alive to hospital. Lethal events from venous
thrombosiswerecapturedinthenationalcauseofdeathregistry.
A diagnosis of venous thrombosis was confirmed through
prescribed anticoagulation therapy recorded in the national
registry of medicinal products for at least four weeks after the
diagnosis. Since 1 January 1994, and validated from 1995,
information on filled prescriptions, including hormonal
contraception, collected by the national registry of medicinal
products has been complete. From this database we obtained
information that had been updated daily on redeemed
prescriptions of hormonal contraception from 1995 to 2010.
We categorised the products in use according to progestogen
type,oestrogendose,androuteofbeingadministered.Duration
of use was estimated from the prescribed defined daily doses
from the date of prescription until the end date of defined daily
doses of the last redeemed prescription or date of a study event.
When hormonal contraception was switched without pause, we
calculated duration as the sum of use before switch and current
use of the new preparation. If a pause lasted for more than four
weeks, we reset the length of use. To account for use before
study start (left censoring bias), we allocated continuous users
of hormonal contraception to the relevant duration of use
category on 1 January 2001 by assessing use before the study
period back to 1995.
Women who used the levonorgestrel intrauterine system were
censored after three years and included again when a new
prescriptionofahormonalcontraceptiveproductwasrecorded.
This was done owing to missing information on removal of
these devices.
Lengthofschoolingandlevelofeducationwereusedasproxies
for social class. Four strata were applied: elementary school
education only, ongoing or completed high school education,
highschoolandongoingorendedmiddlelengtheducation,and
high school and ongoing or ended long education. A fifth
category included women without information on education,
typically the youngest women.
We controlled for calendar year to deal with potential secular
confounding of increasing adiposity by time.
Data on smoking were not available. Smoking is a weak risk
factor for venous thrombosis in young women. However, we
have no reason to believe in preferential prescribing of specific
types of hormonal contraception among smokers. In Denmark
the correlation between smoking and length of education is
strong. Thus, controlling for years of schooling and length of
education may have captured most confounding (if any)
influenced by smoking.
As women treated for infertility with ovarian stimulation drugs
(AnatomicalTherapeuticChemicalcodeG03G)areanticipated
to be at an increased risk of venous thrombosis, we censored
these women during such treatment.
Statistical analysis
UsingmultiplePoissonregressionweanalyseddatainfiveyear
age groups: 15-19, 20-24, and 45-49 years. The non-oral
contraceptiveproductsincludedtransdermalpatchescontaining
norelgestromin (the active metabolite of norgestimate) and
ethinylestradiol, a vaginal ring with etonogestrel (third
generation progestogen) and ethinylestradiol, subcutaneous
implants containing etonogestrel only, and the levonorgestrel
intrauterinesystem(hormoneintrauterinedevice).Tworeference
oral contraceptives with levonorgestrel and norgestimate,
respectively, were assessed for comparison.
We stratified the estimates into three categories according to
length of contraceptive use (<1 year, 1-4 years, >4 years).
Absolute as well as relative risk estimates were calculated. The
reference group for the relative risk estimates was non-users of
alltypesofhormonalcontraception(neverusers+formerusers).
We calculated rate ratios for the different product types, with
users of oral contraceptives containing 30-40 µg oestrogen and
levonorgestrel as reference. Tests for interaction with age and
year were carried out.
Relative risk estimates were adjusted for age, calendar year,
length of schooling and education, and eventually for length of
contraceptive use. For all relative risk estimates and incidence
rateratioswecalculated95%confidencelimits.Wesetthelevel
of significance at P<0.05.
Results
Afterexclusionsandcensoring,1626158non-pregnantwomen
free of previous thrombotic diseases or cancer contributed 9
429 128 woman years of observation. During this time 5287
diagnosesoffirstevervenousthrombosiseventswererecorded,
corresponding to 8.1 per 10 000 woman years. Current users of
hormonal contraception contributed 3 536 946 woman years
and of these, 325 849 concerned non-oral products. Non-users
ofhormonalcontraceptioncontributed5892182womanyears,
with an overall incidence of confirmed venous thrombosis of
2.1 per 10 000 woman years. The incidence of venous
thrombosisincreasedby42.9%duringthe10yearstudyperiod,
or by 4.3% per year (table 1⇓). After adjustment for calendar
yearanduseofhormonalcontraception,theincidenceincreased
by 6.3-fold with increasing age and decreased by 51.2% with
increasing length of education.
Hormonal contraception and venous
thrombosis
Current use of combined oral contraceptives with 30-40 µg
oestrogen and levonorgestrel increased the risk of confirmed
venous thrombosis by 3.2 (2.7 to 3.8), corresponding to an
incidence of 6.2 events per 10 000 exposure years (table 2⇓).
During 6178 woman years, six confirmed events of venous
thrombosis were observed in association with transdermal
combinedcontraceptivepatches,correspondingtoanincidence
of 9.7 per 10 000 exposure years. Compared with non-users of
hormonal contraception, the adjusted relative risk was 7.9 (3.5
to 17.7) and compared with users of oral contraceptives
containinglevonorgestreltherateratiowas2.5(1.1to5.6,tables
2 and 3⇓). After adjustment for length of use, the rate ratio was
reduced to 2.3 (1.0 to 5.2). When compared with oral
contraceptives containing the corresponding progestogen
(norgestimate), the adjusted rate ratio was 2.2 (1.0 to 5.0).
During 50 334 woman years, 39 confirmed venous thrombosis
events were observed with the combined contraceptive vaginal
ring, corresponding to an incidence of 7.8 per 10 000 exposure
years and an adjusted relative risk of 6.5 (4.7 to 8.9) compared
withnon-usersofhormonalcontraception.Comparedwithusers
of combined oral contraceptives with levonorgestrel, the rate
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RESEARCHratio was 2.0 (1.4 to 2.9), which after adjustment for length of
use was reduced to 1.9 (1.3 to 2.7, tables 2 and 3).
During29497womanyears,fiveconfirmedvenousthrombosis
events were observed with progestogen only subcutaneous
implants, corresponding to an incidence rate of 1.7 per 10 000
exposure years and an adjusted relative risk of 1.4 (0.6 to 3.4,
table 2) compared with non-users of hormonal contraception.
Compared with users of combined oral contraceptives with
levonorgestrel, the rate ratio was 0.4 (0.2 to 1.1, table 3).
Theadjustedrelativeriskofconfirmedvenousthrombosiswith
the levonorgestrel intrauterine system was 0.6 (0.4 to 0.8, table
2). Compared with users of combined oral contraceptives with
levonorgestrel, the rate ratio was 0.2 (0.1 to 0.3, table 3).
After stratification according to length of use, the relative risk
of venous thrombosis in women using combined oral
contraceptives was reduced with increasing length of use (table
4⇓). No reduction by time was seen in users of transdermal
combined contraceptive patches or progestogen only
contraception, and no consistent changes were seen for women
who used the vaginal ring.
Discussion
Women who use combined hormonal transdermal patches or
vaginalringsforcontraceptionhavea7.9or6.5timesincreased
riskofvenousthrombosiscomparedwithnon-usersofhormonal
contraception of the same age, corresponding to 9.7 and 7.8
events per 10 000 exposure years. The risk was slightly
increased in women using subcutaneous implants but not in
those using the levonorgestrel intrauterine system.
An incidence rate of confirmed venous thrombosis in users of
transdermal patches of 1 in 1000 exposure years was found in
a recent American study,
11 and a relative risk of 7.9 compared
withnon-usersofhormonalcontraceptionortwicetheriskwith
useofthecorrespondingcombinedoralcontraceptivecontaining
norgestimateinseveralpreviousstudies
11 14-16althoughnotall
12 13
(table 5⇓). These results are supported by pharmacokinetic
studies showing 60% higher plasma levels of oestrogen in
womenwhousetransdermalpatchescomparedwiththoseusing
the corresponding combined oral contraceptive.
17
With an incidence of 7.8 confirmed events per 10 000 exposure
years, the vaginal ring conferred a 90% higher risk of venous
thrombosis than did combined oral contraceptives containing
levonorgestrel, bringing the risk to the same level as that of
combined oral contraceptives with third and fourth generation
progestogens, and compatible with the Food and Drug
Administration study.
11 Supporting our and the FDA results is
the three
18 and five times
19 increase in sex hormone binding
globulin in users of vaginal ring contraception compared with
usersofcombinedoralcontraceptivescontaininglevonorgestrel,
and the activated protein C sensitivity ratio 3.75 times higher
than with oral contraceptives,
19 both considered as surrogate
markers for the risk of venous thrombosis.
The modest non-significant 40% increased relative risk of
venous thrombosis in women using subcutaneous implants is
notsurprising,asothertypesofprogestogenonlycontraception
do not confer an increased risk,
10 and it is less than half the risk
found in users of combined oral contraceptives containing
levonorgestrel.
Thelowriskofvenousthrombosisinusersofthelevonorgestrel
intrauterine system has been shown in previous studies.
7 10 In
the present study this product actually significantly decreased
the risk of venous thrombosis, suggesting that the influence of
progestogen only contraception on risk of venous thrombosis
may depend on dose.
The inconsistent changes with length of use for the non-oral
products could be influenced by the low power in some of the
length of use categories. Another possibility, however, is that
the non-oral route influences the coagulation system and liver
differentially compared with the oral route. Nor did the FDA
report show any consistent change in risk with length of use of
either the patch or the vaginal ring.
The clinical implications of the findings can be expressed in
terms of the number of women who should change their
hormonal contraceptive from the transdermal patch or the
vaginal ring to combined oral contraceptives containing
levonorgestrel to prevent one event of venous thrombosis in a
year.Iftheincidencerateofvenousthrombosisinwomenusing
combinedoralcontraceptivescontaininglevonorgestrelis6per
10 000 exposure years, the vaginal ring is 11 per 10 exposure
years,andthetransdermalpatchis14per10000exposureyears,
then 2000 women using the vaginal ring and 1250 using the
transdermal patch should shift to combined oral contraceptives
with levonorgestrel to prevent one event of venous thrombosis
in one year. A risk of 10 per 10 000 woman years implies a risk
of venous thrombosis of more than 1% over a 10 year user
period.Thereforewomenaregenerallyadvisedtousecombined
oral contraceptives with levonorgestrel or norgestimate, rather
than to use transdermal patches or vaginal rings.
Strengths and limitations of the study
TheinclusionofallDanishnon-pregnantwomenoveradecade
ensures outstanding external validity. Information on use of
hormonalcontraceptionfromaprescriptiondatabaseisthemost
reliable data on exposure available today for four reasons.
Firstly,eachpharmacytransfersdataelectronicallybybarcodes,
eliminatingtypingerrors.Secondly,thecollectionofthesedata
in a central national database is done primarily for
reimbursement purposes and therefore should not be biased by
the pursuit of pharmacoepidemiological studies. Thirdly, the
continued daily update of information on use eliminates recall
bias, as we know from case-control studies, and the problems
of continuous updating of data on exposure in cohort studies.
Fourthly, we eliminated the problem of left censoring bias by
assessing exposure to hormonal contraception over a six year
period before our study started. And we were able to validate
each venous thrombosis event by linking individual data on
diagnosis to succeeding anticoagulation therapy.
We could not control for family disposition or for body mass
index. Adiposity is a well documented risk factor for venous
thrombosis. So far no study has shown any confounding
influence from adiposity, as the rate ratio between hormonal
contraception with different progestogens was not changed in
studies adjusting for this information.
6 8 20
Conclusion
Useoftransdermalpatchesandvaginalringsconferredincidence
rates of 9.7 and 7.8 confirmed venous thromboses per 10 000
exposure years, and relative risks of 7.9 and 6.5 compared with
non-use of hormonal contraception, respectively. A
subcutaneous progestogen only implant may increase the risk
by 40%, whereas the levonorgestrel intrauterine system did not
confer any increased risk, but perhaps even protection.
This study was approved by the Danish Data Protection Agency (J No
2010-41-4778).
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RESEARCHWhat is already known on this topic
Combined oral contraceptives with levonorgestrel or norgestimate confer half the risk of venous thrombosis than oral contraceptives
containing desogestrel, gestodene, or drospirenone
Progestogen only pills do not confer an increased risk of venous thrombosis
What this study adds
Women who use combined contraceptive transdermal patches are at an increased risk of venous thrombosis about eight times that of
non-users of hormonal contraception, corresponding to 9.7 events per 10 000 exposure years
Vaginal rings increased the risk of venous thrombosis 6.5 times compared with non-use of hormonal contraception, corresponding to
7.8 events per 10 000 exposure years
The risk of venous thrombosis was not significantly increased with use of subcutaneous implants or the levonorgestrel intrauterine
system compared with non-use of hormonal contraception
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Table 1| Crude incidence rate and adjusted relative risk of confirmed venous thrombosis according to age, calendar year, and length of
education
P value Adjusted relative risk* (95% CI) Incidence per 10 000 woman years
Venous thrombosis
Woman years Variables Confirmed All
Age:
<0.001 0.16 (0.13 to 0.19) 1.79 251 365 1 403 925 15-19
<0.001 0.19 (0.16 to 0.22) 2.72 326 479 1 198 098 20-24
<0.001 0.30 (0.27 to 0.33) 3.38 387 594 1 145 729 25-29
<0.001 0.44 (0.40 to 0.48) 3.45 448 715 1 299 645 30-34
<0.001 0.60 (0.55 to 0.66) 3.98 601 930 1 509 447 35-39
<0.001 0.82 (0.75 to 0.89) 4.67 705 1105 1 510 042 40-44
— 1.00 (reference) 5.26 716 1099 1 362 242 45-49
Year:
<0.001 0.70 (0.61 to 0.79) 3.17 315 444 994 095 2001
<0.001 0.72 (0.64 to 0.82) 3.38 331 466 979 715 2002
<0.001 0.68 (0.60 to 0.77) 3.16 304 438 963 470 2003
<0.001 0.79 (0.70 to 0.89) 3.35 319 512 953 604 2004
0.0005 0.81 (0.72 to 0.91) 3.85 362 525 939 935 2005
0.0028 0.84 (0.74 to 0.94) 3.90 363 537 929 975 2006
0.6531 0.97 (0.87 to 1.09) 4.24 391 615 921 713 2007
0.0171 0.87 (0.77 to 0.98) 3.78 347 538 918 349 2008
0.6597 0.98 (0.87 to 1.09) 4.00 365 599 911 825 2009
— 1.00 (reference) 3.68 337 613 916 449 2010
Education:
0.0004 1.25 (1.11 to 1.42) 5.35 1159 1819 2 164 635 1 (low)
<0.001 0.72 (0.62 to 0.83) 3.06 314 475 1 026 525 2
0.0087 0.83 (0.73 to 0.95) 4.35 974 1456 2 236 972 3
<0.001 0.61 (0.53 to 0.71) 2.76 382 602 1 385 214 4 (high)
— 1.00 (reference) 2.31 605 935 2 615 782 Not available
*Adjusted for age, calendar year, education, and use of hormonal contraception.
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RESEARCHTable 2| Crude incidence rate and adjusted relative risk of venous thrombosis in current users of non-oral hormonal contraception and
combined oral contraceptives (COC) with non-users as reference
P value Adjusted relative risk* (95% CI)
Incidence per 10 000
exposure years
No with venous
thrombosis Woman years Outcome, contraception type
All venous thromboses:
— 1.00 (reference) 3.84 2262 5 892 182 Non-use
<0.001 2.37 (2.05 to 2.74) 8.68 201 231 675 COC with levonorgestrel and
30-40 µg oestrogen
<0.001 2.63 (2.27 to 3.05) 6.63 198 298 566 COC with norgestimate
<0.001 4.40 (2.09 to 9.24) 11.33 7 6178 Patch
<0.001 4.29 (3.27 to 5.62) 10.93 55 50 334 Vaginal ring
0.005 2.08 (1.25 to 3.46) 5.09 15 29 497 Implant
0.040 0.80 (0.65 to 0.99) 3.67 88 239 841 Levonorgestrel IUS
Confirmed events:
— 1.00 (reference) 2.05 1209 5 892 182 Non-use
<0.001 3.21 (2.70 to 3.81) 6.22 144 231 675 COC with levonorgestrel and
30-40 µg oestrogen
<0.001 3.57 (2.98 to 4.27) 4.52 135 298 566 COC with norgestimate
<0.001 7.90 (3.54 to 17.65) 9.71 6 6178 Patch
<0.001 6.48 (4.69 to 8.94) 7.75 39 50 334 Vaginal ring
0.450 1.40 (0.58 to 3.38) 1.70 5 29 497 Implant
0.002 0.57 (0.41 to 0.81) 1.38 33 239 841 Levonorgestrel IUS
Patch=transdermal contraceptive patch (EVRA; Johnson & Johnson, NJ, USA); implant=subcutaneous implant (Implanon; MSD; NJ, USA); vaginal ring=combined
hormonal vaginal ring (NuvaRing; MSD, NJ, USA); levonorgestrel IUS=levonorgestrel intrauterine system (Mirena: Bayer Pharma, Berlin, Germany).
*Adjusted for age, calendar year, and education.
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RESEARCHTable 3| Rate ratio estimates of venous thrombosis between users of different types of non-oral hormonal contraception and users of
combined oral contraceptives (COC) with levonorgestrel and 30-40 µg oestrogen (reference group)
P value Adjusted rate ratio (95% CI)*
No with venous
thrombosis Woman years Outcome, contraception type
All venous thrombosis:
— 1.00 (reference) 201 231 675 COC with levonorgestrel and 30-40 µg
oestrogen
0.305 1.11 (0.91 to 1.35) 198 298 566 COC with norgestimate
0.109 1.85 (0.87 to 3.94) 7 6178 Patch
0.0001 1.81 (1.34 to 2.44) 55 50 334 Vaginal ring
0.623 0.88 (0.52 to 1.48) 15 29 497 Implant
<0.001 0.34 (0.26 to 0.43) 88 239 841 Levonorgestrel IUS
Confirmed events:
— 1.00 (reference) 144 231 675 COC with levonorgestrel and 30-40 µg
oestrogen
0.378 1.11 (0.88 to 1.41) 135 298 566 COC with norgestimate
0.031 2.46 (1.09 to 5.58) 6 6178 Patch
0.0001 2.02 (1.41 to 2.89) 39 50 334 Vaginal ring
0.070 0.44 (0.18 to 1.07) 5 29 497 Implant
<0.001 0.18 (0.12 to 0.26) 33 239 841 Levonorgestrel IUS
Confirmed events adjusted for length of use:
— 1.00 (reference) 144 231 675 COC with levonorgestrel and 30-40 µg
oestrogen
0.465 1.09 (0.86 to 1.38) 135 298 566 COC with norgestimate
0.045 2.31 (1.02 to 5.23) 6 6178 Patch
0.001 1.90 (1.33 to 2.71) 39 50 334 Vaginal ring
0.064 0.43 (0.18 to 1.05) 5 29 497 Implant
<0.001 0.18 (0.12 to 0.26) 33 239 841 Levonorgestrel IUS
Patch=transdermal contraceptive patch (EVRA; Johnson & Johnson, NJ, USA); implant=subcutaneous implant (Implanon; MSD; NJ, USA); vaginal ring=combined
hormonal vaginal ring (NuvaRing; MSD, NJ, USA); levonorgestrel IUS=levonorgestrel intrauterine system (Mirena; Bayer Pharma, Berlin, Germany).
*Adjusted for age, calendar year, and education.
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RESEARCHTable 4| Relative risk of confirmed venous thrombosis in current users of different types of hormonal contraception according to length
of use
Adjusted relative risk (95% CI)*
No with confirmed
venous thrombosis Hormonal contraception >4 years 1-4 years <1 year
1 (reference) 1 (reference) 1 (reference) 1209 Non-use
2.71 (2.06 to 3.58) 3.07 (2.28 to 4.13) 4.25 (3.17 to 5.69) 144 COC with levonorgestrel and
30-40 µg oestrogen
2.67 (1.82 to 3.92) 2.97 (2.19 to 4.03) 4.97 (3.86 to 6.39) 135 COC with norgestimate
NA 11.9 (3.82 to 36.9) 6.89 (2.22 to 21.4) 6 Patch
5.37 (1.73 to 16.7) 3.83 (1.91 to 7.69) 8.36 (5.73 to 12.2) 39 Vaginal ring
NA 1.43 (0.46 to 4.45) 1.63 (0.41 to 6.52) 5 Implant
NA 0.61 (0.39 to 0.94) 0.59 (0.34 to 1.05) 33 Levonorgestrel IUS
COC=combined oral contraceptive; patch=transdermal contraceptive patch (EVRA; Johnson & Johnson, NJ, USA); implant=subcutaneous implant (Implanon;
MSD, NJ, USA); vaginal ring=combined hormonal vaginal ring (NuvaRing; MSD; NJ, USA); levonorgestrel IUS=levonorgestrel intrauterine system (Mirena; Bayer
Pharma, Berlin, Germany); NA=not available.
*Adjusted for age, calendar year, and education.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;344:e2990 doi: 10.1136/bmj.e2990 (Published 10 May 2012) Page 8 of 9
RESEARCHTable 5| Incidence of venous thrombosis in users of transdermal contraceptive patch and corresponding combined oral contraceptive
(COC) with norgestimate, and rate ratio of venous thrombosis in users of patch versus users of combined oral contraceptives with
norgestimate
Rate ratio (95% CI)
Incidence per 10 000 exposure years
No with venous thrombosis Sampling period Study COC with norgestimate Patch
1.1 (0.7 to 1.8) 4.2 5.3 68 2002-05 Jick 2006
12
1.1 (0.6 to 2.1) NA NA 56 2002-06 Jick 2007
13
2.4 (1.2 to 5.0) NA NA 38 2002-07 Jick 2010
14
2.2 (1.3 to 3.8) 1.8 4.1 57 2002-04 Cole 2007
15
2.0 (1.2 to 3.3) NA NA 201 2002-06 Dore 2010
16
1.3* (0.9 to 1.7) 6.6* 9.6 625 2001-07 FDA 2011
11
2.2 (1.0 to 5.0) 4.5 9.7 3434 2001-10 Lidegaard 2011
10
NA=not available; FDA=Food and Drug Administration.
*Reference group was users of combined oral contraceptives with levonorgestrel and 30-40 µg oestrogen.
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RESEARCH